# Earkart (NSE: EARKART) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/EARKART · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹182 Cr, it ranks 2332nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.

Its return on equity was 34.6% in FY25. Promoters held 57.34% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹182 Cr |
| ROE | 34.6% (FY25) |
| ROCE | 46.9% (FY25) |
| Debt to equity | 0.25 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹43 Cr | ₹7 Cr |
| FY24 | ₹32 Cr | ₹3 Cr |
| FY23 | ₹29 Cr | ₹1 Cr |
| FY22 | ₹6 Cr | ₹0 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 57.34%
- Domestic institutions: 21.95%
- Non-institutions: 20.71%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | — | — |
| [OXYGENTA PHARMA](https://app.pivotnow.in/stock/OXYGENTAPH) | — | ₹185 Cr | — | — |
| [Accretion Nutra](https://app.pivotnow.in/stock/ANL) | — | ₹184 Cr | — | — |
| [Novelix Pharma](https://app.pivotnow.in/stock/NOVELIX) | — | ₹181 Cr | — | — |
| [Medico Remedies](https://app.pivotnow.in/stock/MEDICO) | ₹21.68 | ₹180 Cr | 13.7 | — |
| [Take Solutions](https://app.pivotnow.in/stock/TAKE) | ₹11.96 | ₹177 Cr | 41.2 | — |

## Questions and answers

### What is the market cap of Earkart?

Earkart's market capitalisation is ₹182 Cr (₹182 Cr) at the 19 Oct 2026 close, ranking 2332nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Earkart?

Return on equity was 34.6% in FY25 and return on capital employed was 46.9% in FY25 (standalone figures).

### Is Earkart a debt-free company?

No. Earkart's debt-to-equity ratio was 0.25 in FY25, with total debt of ₹0 Cr.

### What is the shareholding pattern of Earkart?

As of 31 Mar 2026: promoters 57.34%, domestic institutions 21.95%, non-institutions 20.71%.

### Who are Earkart's competitors?

The listed Pharma & Healthcare companies closest to Earkart by market cap are Aashka Hospital, OXYGENTA PHARMA, Accretion Nutra, Novelix Pharma, Medico Remedies and Take Solutions.

### Is Earkart a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Earkart's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EARKART against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.